BridgeBio Pharma revenue and financials
$66.96Change from previous close: +1.24%Absolute change: +$0.82
In the fiscal year ended December 2025, BridgeBio Pharma reported revenue of $502.08M (+126.26% year over year). The net loss was $732.94M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +126.26%
- 2025 vs 2024
- Net margin
- -146.0%
- 2024: -244.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -71.1 | -197 | -56.4 | -110 | -80.7 | -199 | -195 | -181 | 74.7 | -220 | -125 | -145 |
| Depreciation and amortization | 1.1 | 1.2 | 1.4 | 1.4 | 1.3 | 1.3 | 1.4 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 |
| Capital expenditure | -0.4 | -0.1 | -0.0 | -0.5 | -0.6 | — | -0.0 | -0.1 | -0.1 | -0.7 | -0.4 | -0.4 |
| Investing cash flow | 17.9 | -42.7 | -14.4 | 4.5 | -13.0 | -1.6 | -3.2 | 38.2 | 3.0 | 22.8 | -0.1 | 37.7 |
| Financing cash flow | -149 | 550 | -2.2 | -0.9 | 302 | 60.3 | 474 | 0.7 | -5.7 | 280 | -4.5 | 307 |
| Share repurchases | -132 | -86.6 | -7.4 | -3.0 | -2.0 | -50.1 | -1.4 | -1.4 | -2.0 | -2.9 | -2.6 | -2.6 |
| Debt issued | 0.0 | 633 | 0.0 | 0.0 | 300 | 575 | 500 | — | — | 450 | — | — |
| Debt repaid | -33.1 | 0.0 | 0.0 | 0.0 | -2.0 | -459 | — | — | — | -473 | — | — |
| Net change in cash | -202 | 310 | -73.0 | -106 | 208 | -141 | 275 | -142 | 72.0 | 82.8 | -129 | 199 |
| Free cash flow | -71.5 | -197 | -56.5 | -110 | -81.3 | -199 | -195 | -181 | 74.6 | -220 | -125 | -146 |
| Levered free cash flow | -50.9 | -171 | -20.3 | -74.8 | -48.6 | -178 | 33.6 | -104 | -13.6 | -207 | -45.3 | -82.4 |